Browse News
Filter News
Found 722,863 articles
-
On Wednesday evening, a man in Massachusetts became the first person reported to have a case of monkeypox in the U.S. The man contracted monkeypox after traveling to Canada.
-
Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.
-
Germany-based Evotec AG forged its third partnership in May, a deal with Spain’s Almirall S.A. to develop new therapeutics for severe diseases of the skin.
-
As the American Society of Gene & Cell Therapy's 25th Annual Meeting wraps up, a host of life science companies touted their research and products. BioSpace looks at some of them.
-
Zealand Pharma shared positive top-line results for its second Phase III clinical trial of its congenital hyperinsulinism (CHI) drug, dasiglucagon, in pediatric patients.
-
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
-
Enanta Pharmaceuticals' attempt to find an effective treatment for respiratory syncytial virus (RSV) met a roadblock after its candidate failed to meet the primary endpoint in Phase II.
-
GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.
-
Pfizer, Sarepta Therapeutics, Genethon and Solid Biosciences are working on gene therapies for Duchenne Muscular Dystrophy. Now, the four companies have teamed up.
-
Spruce Biosciences is developing what could be the first new therapy treating congenital adrenal hyperplasia (CAH) since the 1960s, and a new therapy for women with polycystic ovary syndrome.
-
Maxwell Serowoky has observed an increase in Sonic Hedgehog (Shh) gene activity during rib bone recovery, expanding the gene’s function beyond the known role of embryogenesis.
-
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
-
In a Phase IIb study, data showed that Prota Therapeutics' oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
-
Rafael Pharmaceuticals, Inc. Announces Corporate Name Change to Cornerstone Pharmaceuticals, Inc.
5/19/2022
Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the development of rare cancer therapeutics, today announced that it is changing its name to Cornerstone Pharmaceuticals, Inc.
-
Biora Therapeutics Announces New Patents for Targeted Therapeutics PlatformMarks 29 Patents Worldwide Directed to Biora’s Device Localization Technology
5/19/2022
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced a new patent related to its Drug Delivery System (DDS) platform under development.
-
KRAS Inhibitor Sotorasib Drug Market Drug Sales Forecast Report 2028
5/19/2022
Kirsten rat sarcoma viral oncogene homologue (KRAS) is one of the most often mutated genes in several cancers such as lung cancer, colorectal cancer, pancreatic cancer, and others.
-
CellCarta expands it proteomics portfolio with the acquisition of next-generation immuno-MRM assays from Precision Assays
5/19/2022
This acquisition solidifies CellCarta's leadership position in proteomics services with a unique combination of validated set of reagents and multiplex assays, including pathway specific off-the-shelf panels, allowing for clinical protein quantification covering a comprehensive range of immuno-oncology targets.
-
Global PARP Inhibitors Drug Therapy Market Forecast 2028
5/19/2022
Poly ADP-Ribose Polymerase (PARP) inhibitors are long chain containing 17 enzymes that combine several (poly) units of ADP-ribose in a chain and transfer them to the target proteins.
-
AIkido Pharma Announces Company Commitment to Board Diversity
5/19/2022
AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the Company's commitment to complying with the NASDAQ listing requirements on board diversity by August 1, 2022.
-
Lymphoma Antibodies Market Clinical Trials Report 2028
5/19/2022
The advent of antibody therapeutics represents breakthrough therapy in the management of wide range of cancers including various subtypes of lymphoma.